Rosenblatt Maintains Buy on Meta Platforms, Raises Price Target to $886
Rosenblatt analyst Barton Crockett maintains Meta Platforms (NASDAQ:META) with a Buy and raises the price target from $883 to $886.
Read original at benzingaMarkets · News reference
8-K filing — WISCONSIN PUBLIC SERVICE CORP
Filed: 2026-08-13 AccNo: 0001104659-26-095547 Size: 527 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
No ticker was attached by the source feed.
- Source
- edgar
- Observed
- Aug 13, 2026, 1:21 PM
- Checked
- Aug 13, 2026, 1:21 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Adicet Bio Reveals FDA Clearance Of IND Application For ADI-212; Co Plans To Initiate Phase 1 Enrollment In Patients With mCRPC In Q4 Of 2026
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid
Read original at benzingaWorkday Q2 Adj. EPS $2.75 Beats $2.61 Estimate, Sales $2.649B Beat $2.636B Estimate
Workday (NASDAQ:WDAY) reported quarterly earnings of $2.75 per share which beat the analyst consensus estimate of $2.61 by 5.36 percent. This is a 24.43 percent increase over earnings of $2.21 per share from the same
Read original at benzingaAutodesk Q2 Adj. EPS $3.30 Beats $3.12 Estimate, Sales $2.046B Beat $2.012B Estimate
Autodesk (NASDAQ:ADSK) reported quarterly earnings of $3.30 per share which beat the analyst consensus estimate of $3.12 by 5.77 percent. This is a 25.95 percent increase over earnings of $2.62 per share from the same
Read original at benzingaAutodesk Sees Q3 GAAP EPS $1.57-$1.87 vs $2.16 Est
Autodesk (NASDAQ:ADSK) is looking for Q3 GAAP EPS of $1.57-$1.87 vs $2.16 analyst estimate..
Read original at benzingaModerna Says FDA Approved sBLAs For 2026-2027 Spikevax And mNEXSPIKE Formulas Targeting JN.1-Lineage XFG Subvariant; Says Vaccines Expected Available In Coming Days
Read original at benzinga